MannKind Wins FDA Approval for Afrezza in Children, Opening Pediatric Diabetes Market
31/5 05:07
MannKind (NASDAQ:MNKD) said the U.S. Food and Drug Administration has approved Afrezza for pediatric patients with diabetes ages 6 and older, expanding the inhaled mealtime insulin’s label into children and adolescents. Chief Executive Officer Michael Castagna called the decisio...